Fluoxetine (LY-110140) is a highly specific serotonin uptake inhibitor and selective 5-hydroxytryptamine (5-HT) reuptake inhibitor. Fluoxetine has antidepressant activity.

METHODS: Mouse cortical near-pure neuronal cell cultures were treated with Fluoxetine (3-30 µM) for 24 h. Cell viability was measured by MTT assay.
RESULTS: Fluoxetine induced neuronal death in a concentration-dependent manner. [1]
METHODS: Human gastric cancer cells AGS were treated with Fluoxetine (10-20 µM) for 24 h. Apoptosis was detected by Flow cytometry.
RESULTS: The number of early apoptotic cells in Fluoxetine-treated group was significantly increased by about 4-fold and 10-fold, respectively. [2]

METHODS: To assay antidepressant activity in vivo, Fluoxetine (2.5-10 mg/kg) was administered intraperitoneally to MRL/MpJ mice twice daily for twenty-six days.
RESULTS: Chronic treatment with 5 and 10 mg/kg Fluoxetine significantly increased cell proliferation and BDNF levels in the hippocampus. Only chronic treatment with the highest Fluoxetine increased BDNF levels in the frontal cortex. [3]
METHODS: To test antidepressant activity in vivo, Fluoxetine (18 mg/kg) was administered orally once daily for three weeks to a model of corticosterone-induced anxiety/depression-like behavior in C57BL/6Ntac mice.
RESULTS: Chronic Fluoxetine treatment reversed the anxiety phenotype. Regarding total distance traveled, chronic corticosterone treatment showed a nonsignificant trend that was eliminated by chronic Fluoxetine treatment. [4]